首页> 美国卫生研究院文献>EClinicalMedicine >First-in-human study of the safety pharmacokinetics and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

【2h】

First-in-human study of the safety pharmacokinetics and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

机译：单独和先进肿瘤中的紫杉烷的一类脂肪酸合酶抑制剂TVB-2640的安全性药代动力学和药效学和药效学的先进性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane.

机译：我们与口腔FasN抑制剂TVB-2640进行了一对人类剂量升级研究，以确定最大耐受剂量（MTD）和推荐的2剂量（RP2D），作为单药治疗和紫杉烷。

著录项

期刊名称 EClinicalMedicine
作者
Gerald Falchook; Jeffrey Infante; Hendrik-Tobias Arkenau; Manish R. Patel; Emma Dean; Erkut Borazanci; Andrew Brenner; Natalie Cook; Juanita Lopez; Shubham Pant; Arthur Frankel; Peter Schmid; Kathleen Moore; William McCulloch; Katharine Grimmer; Marie OFarrell; George Kemble; Howard Burris;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类
关键词

机译：乳腺癌;妇科癌症;肺癌;生物标志物;药物机制;药理学;小分子剂;临床试验;

相似文献

外文文献
中文文献
专利

1. Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 [J] . Infante J., Patel M., Von Hoff D., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：一级脂肪酸合酶（FASN）抑制剂TVB-2640的首次人体研究的初步报告
2. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors [J] . Martinez-GarciaM., BanerjiU., AlbanellJ., Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第17期

机译：首次在人体内进行I期剂量递增研究，RO5126766是实体瘤患者中一流的双重MEK / RAF抑制剂RO5126766的安全性，药代动力学和药效学
3. 365 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour [J] . J.C. Soria, U. Banerji, R. Bahleda, European Journal of Cancer Supplements . 2010,第7期

机译：365先进的RAF / MEK双重双重抑制剂RO5126766在晚期或转移性实体瘤患者中的首次人类，安全性，药效学（PD）和药代动力学（PK）试验
4. Targeting fatty acid synthase to inhibit tumor growth and overcome taxane resistance [C] . Joshua J. Souchek, Lindsey Muraskin, Lucas Houser, Visualizing and Quantifying Drug Distribution in Tissue III . 2019

机译：靶向脂肪酸合酶以抑制肿瘤生长并克服紫杉烷抗性
5. Identification of the conjugated linoleic acid isomer responsible for inhibiting essential fatty acid metabolism and tumor cell growth. [D] . Ma, David Won Lung. 2001

机译：鉴定了抑制必需脂肪酸代谢和肿瘤细胞生长的共轭亚油酸异构体。
6. Safety tolerability pharmacokinetics and pharmacodynamics of the afucosylated humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors [O] . Kohei Shitara, Taroh Satoh, Satoru Iwasa, 2019

机译：无岩藻糖基化的人源化抗EPHA2抗体DS-8895a的安全性耐受性药代动力学和药效学：在患有晚期实体瘤的患者中进行的人体内第一阶段I剂量递增和剂量扩展研究
7. First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors [O] . Maria Martinez-Garcia, Udai Banerji, Joan Albanell, 2012

机译：首先，第一期，I期升级的安全，药代动力学和RO5126766的药效学，是固体肿瘤患者的一类级别双MEK / RAF抑制剂

First-in-human study of the safety pharmacokinetics and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

摘要

著录项

相似文献

相关主题

期刊订阅